Pharma & biotech

Sanofi upgrades 2021 guidance after sales of Dupixent and diabetes products increase

France-based pharmaceutical company Sanofi reported progress on its top line and increasing sales of eczema treatment Dupixent and diabetes products in its quarterly report. The firm is therefore upgrading its guidance for the year.
Photo: BENOIT TESSIER/REUTERS / X02011
Photo: BENOIT TESSIER/REUTERS / X02011
BY CHRISTOFFER DUE KARLSSON, TRANSLATED BY CATHERINE BRETT

Sanofi is upgrading its financial guidance for the rest of the year, now expecting growth in earnings per share of around 12 percent excluding currency fluctuations (at Constant Exchange Rates, CER). It previously expected growth of 6-9 percent.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
    • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Related articles

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading

    Jobs